Cargando…

SURINPARK: Safinamide for Urinary Symptoms in Parkinson’s Disease

Background: Urinary symptoms are common, disabling and generally unresponsive to treatment in Parkinson´s disease (PD). Safinamide is approved as an add-on therapy to levodopa to improve fluctuations. Methods: Retrospective analysis of electronic records of nondemented PD patients seen consecutively...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gómez-López, Ana, Sánchez-Sánchez, Arantxa, Natera-Villalba, Elena, Ros-Castelló, Victoria, Beltrán-Corbellini, Álvaro, Fanjul-Arbós, Samira, Pareés Moreno, Isabel, López-Sendon Moreno, José Luis, Martínez Castrillo, Juan Carlos, Alonso-Canovas, Araceli
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7825064/ https://www.ncbi.nlm.nih.gov/pubmed/33418858 http://dx.doi.org/10.3390/brainsci11010057

Ejemplares similares

¿Qué piensan los estudiantes de Medicina sobre los trastornos neurológicos funcionales?
por: Escribano-Paredes, José B., et al.
Publicado: (2023)

Switching from Rasagiline to Safinamide as an Add-On Therapy Regimen in Patients with Levodopa: A Literature Review
por: Sanchez Alonso, Pilar, et al.
Publicado: (2023)

Impulse Control Disorders in Parkinson's Disease: Has COVID‐19 Related Lockdown Been a Trigger?
por: Rábano‐Suárez, Pablo, et al.
Publicado: (2021)

COVID-19 in Parkinson’s disease: what holds the key?
por: Sainz-Amo, R., et al.
Publicado: (2020)

Impact of SAfinamide on Depressive Symptoms in Parkinson’s Disease Patients (SADness-PD Study): A Multicenter Retrospective Study
por: Peña, Esteban, et al.
Publicado: (2021)

Incobotulinumtoxin A for Sialorrhea in Neurological Disorders: A Real-Life Experience
por: Martínez-Poles, Javier, et al.
Publicado: (2018)

Use of the Cardiovascular Polypill in Secondary Prevention of Cerebrovascular Disease: A Real-Life Tertiary Hospital Cohort Study of 104 Patients
por: Ros-Castelló, Victoria, et al.
Publicado: (2020)

The effects of safinamide on dysphagia in Parkinson’s disease
por: Hirano, Makito, et al.
Publicado: (2023)

Safinamide: an add-on treatment for managing Parkinson’s disease
por: Müller, Thomas
Publicado: (2018)

High versus standard doses of corticosteroids in severe COVID-19: a retrospective cohort study
por: Monreal, Enric, et al.
Publicado: (2020)

Safinamide improves sleep and daytime sleepiness in Parkinson’s disease: results from the SAFINONMOTOR study
por: Santos García, Diego, et al.
Publicado: (2021)

Pain Improvement in Parkinson’s Disease Patients Treated with Safinamide: Results from the SAFINONMOTOR Study
por: Santos García, Diego, et al.
Publicado: (2021)

Safinamide Improves Non-Motor Symptoms Burden in Parkinson’s Disease: An Open-Label Prospective Study
por: Santos García, Diego, et al.
Publicado: (2021)

Investigational agents in the treatment of Parkinson’s disease: focus on safinamide
por: Malek, Naveed M, et al.
Publicado: (2012)

Adjuvant therapies for Parkinson’s disease: critical evaluation of safinamide
por: Stocchi, Fabrizio, et al.
Publicado: (2016)

Emerging approaches in Parkinson’s disease – adjunctive role of safinamide
por: Müller, Thomas
Publicado: (2016)

Effects of safinamide on pain in patients with fluctuating Parkinson's disease
por: Grigoriou, Sotirios, et al.
Publicado: (2021)

The Current Evidence for the Use of Safinamide for the Treatment of Parkinson's Disease
por: Abbruzzese, Giovanni, et al.
Publicado: (2021)

Impact of Safinamide on Patient-Reported Outcomes in Parkinson’s Disease
por: Espinoza-Vinces, Christian, et al.
Publicado: (2023)

The effects of safinamide according to gender in Chinese parkinsonian patients
por: Pellecchia, M. T., et al.
Publicado: (2023)

Post‐Hypoxic Myoclonus after COVID‐19 Infection Recovery
por: Ros‐Castelló, Victoria, et al.
Publicado: (2020)

Effectiveness of Safinamide over Mood in Parkinson’s Disease Patients: Secondary Analysis of the Open-label Study SAFINONMOTOR
por: Labandeira, Carmen M., et al.
Publicado: (2021)

Population pharmacokinetic and pharmacodynamic analyses of safinamide in subjects with Parkinson's disease
por: Loprete, Luca, et al.
Publicado: (2016)

Long-Term Effects of Safinamide on Mood Fluctuations in Parkinson’s Disease
por: Cattaneo, Carlo, et al.
Publicado: (2017)

Long-term Efficacy of Safinamide on Parkinson’s Disease Chronic Pain
por: Cattaneo, Carlo, et al.
Publicado: (2018)

Safinamide in Clinical Practice: A Spanish Multicenter Cohort Study
por: Martí-Andrés, Gloria, et al.
Publicado: (2019)

Efficacy of Safinamide and Gender Differences During Routine Clinical Practice
por: Pellecchia, Maria T., et al.
Publicado: (2021)

The Efficacy of Safinamide in the Management of Parkinson's Disease: A Systematic Review
por: Sharaf, Joudi, et al.
Publicado: (2022)

Fatigue in fluctuating Parkinson’s disease patients: possible impact of safinamide
por: Pauletti, Caterina, et al.
Publicado: (2023)

Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations
por: Borgohain, Rupam, et al.
Publicado: (2014)

A Spanish Consensus on the Use of Safinamide for Parkinson’s Disease in Clinical Practice
por: Pagonabarraga, Javier, et al.
Publicado: (2020)

Safinamide in the treatment pathway of Parkinson’s Disease: a European Delphi Consensus
por: Stocchi, Fabrizio, et al.
Publicado: (2022)

Levodopa Equivalent Dose of Safinamide: A Multicenter, Longitudinal, Case–Control Study
por: Cilia, Roberto, et al.
Publicado: (2023)

Chimeric Agents Derived from the Functionalized Amino Acid, Lacosamide, and the α-Aminoamide, Safinamide: Evaluation of Their Inhibitory Actions on Voltage-Gated Sodium Channels, and Antiseizure and Antinociception Activities and Comparison with Lacosamide and Safinamide
por: Park, Ki Duk, et al.
Publicado: (2014)

PedaleoVR: Usability study of a virtual reality application for cycling exercise in patients with lower limb disorders and elderly people
por: Rojo, Ana, et al.
Publicado: (2023)

ISCHEMIA Trial: Key Questions and Answers
por: Lopez-Sendon, Jose, et al.
Publicado: (2021)

Case Report: Barely Able to Speak, Can’t Stop Echoing: Echolalic Dynamic Aphasia in Progressive Supranuclear Palsy
por: Berthier, Marcelo L., et al.
Publicado: (2021)

Effects of Safinamide on Pain in Fluctuating Parkinson’s Disease Patients: A Post-Hoc Analysis
por: Cattaneo, Carlo, et al.
Publicado: (2017)

Establishment of a sensitive UPLC-MS/MS method to quantify safinamide in rat plasma
por: Wang, Ying, et al.
Publicado: (2023)

Safinamide in the management of patients with Parkinson’s disease not stabilized on levodopa: a review of the current clinical evidence
por: Bette, Sagari, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_gd31v9vq09qus5cbmohq1ea0t9